angeliq 1 mg/1 tableta+ 2 mg/1 tableta film tableta
bayer d.o.o. sarajevo - drospirenon, estradiol - film tableta - 1 mg/1 tableta+ 2 mg/1 tableta - 1 film tableta sadrži: 1 mg estradiola (u obliku estradiol, hemihidrata) i 2 mg drospirenona
thyrogen
sanofi b.v. - tirotropin alfa - neoplazme štitnjače - prednje hipofize hormoni i analozi, hipofize i гипоталамические hormoni i analozi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.
verzenios
eli lilly nederland b.v. - abemaciclib - neoplazme dojki - antineoplastična sredstva - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
omnitrope 5 mg/1.5 ml rastvor za injekciju u patroni
novartis ba d.o.o. - somatropin - rastvor za injekciju u patroni - 5 mg/1.5 ml - 1,5 ml rastvora za injekciju u patroni sadrži: 5 mg somatropina
omnitrope 10 mg/1.5 ml rastvor za injekciju u patroni
novartis ba d.o.o. - somatropin - rastvor za injekciju u patroni - 10 mg/1.5 ml - 1,5 ml rastvor za injekciju u patroni sadrži: 10 mg somatropina
omnitrope 15 mg/1.5 ml rastvor za injekciju u patroni
novartis ba d.o.o. - somatropin - rastvor za injekciju u patroni - 15 mg/1.5 ml - 1,5 ml rastvora za injekciju u patroni sadrži: 15 mg somatropina
omnitrope 10 mg/1.5 ml rastvor za injekciju u patroni
sandoz d.o.o. - somatropin - rastvor za injekciju u patroni - 10 mg/1.5 ml - 1,5 ml rastvor za injekciju u patroni sadrži: 10 mg somatropina
ibrance
pfizer europe ma eeig - palbociclib - neoplazme dojki - antineoplastična sredstva - ibrance indiciran za liječenje hormonalnih receptora (op) je pozitivan, людское эпидермическое ako uređaj primatelja 2 faktor rasta (her2 i) negativne lokalno-uobičajena ili metastatskih tumora dojke:u kombinaciji s inhibitor aromataze, u kombinaciji s fulvestrant kod žena koje su dobili preliminarne hormonsko nadomjesno liječenje. u pre - ili perimenopauzi, endokrini terapija mora biti u kombinaciji s luteinizirajućeg hormona releasing hormon (lhrh) agonist.
norditropin simplexx 10 mg/1,5 ml otopina za injekciju u ulošku
novo nordisk a/s, novo alle, bagsvaerd, danska - соматропин - otopina za injekciju u ulošku - 10 mg/1,5 ml - urbroj: jedan ml otopine sadrži 6,7 mg somatropina
norditropin simplexx 15 mg/1,5 ml otopina za injekciju u ulošku
novo nordisk a/s, novo alle, bagsvaerd, danska - соматропин - otopina za injekciju u ulošku - 15 mg/1,5 ml - urbroj: jedan ml otopine sadrži 10 mg somatropina